D Agarwal, S Pineda, K Michailidou, J Herranz, G Pita, LT Moreno, MR Alonso, J Dennis, Q Wang, MK Bolla, KB Meyer, P Menéndez-Rodríguez, D Hardisson, M Mendiola, A González-Neira, A Lindblom, S Margolin, A Swerdlow, A Ashworth, N Orr, M Jones, K Matsuo, H Ito, H Iwata, N Kondo, kConFab Investigators, Australian Ovarian Cancer Study Group, M Hartman, M Hui, WY Lim, PT-C Iau, E Sawyer, I Tomlinson, M Kerin, N Miller, D Kang, J-Y Choi, SK Park, D-Y Noh, JL Hopper, DF Schmidt, E Makalic, MC Southey, SH Teo, CH Yip, K Sivanandan, W-T Tay, H Brauch, T Brüning, U Hamann, GENICA Network, AM Dunning, M Shah, IL Andrulis, JA Knight, G Glendon, S Tchatchou, MK Schmidt, A Broeks, EH Rosenberg, LJ van't Veer, PA Fasching, SP Renner, AB Ekici, MW Beckmann, C-Y Shen, C-N Hsiung, J-C Yu, M-F Hou, W Blot, Q Cai, AH Wu, C-C Tseng, D Van Den Berg, DO Stram, A Cox, IW Brock, MWR Reed, K Muir, A Lophatananon, S Stewart-Brown, P Siriwanarangsan, W Zheng, S Deming-Halverson, MJ Shrubsole, J Long, X-O Shu, W Lu, Y-T Gao, B Zhang, P Radice, P Peterlongo, S Manoukian, F Mariette, S Sangrajrang, J McKay, FJ Couch, AE Toland, TNBCC, D Yannoukakos, O Fletcher, N Johnson, I dos Santos Silva, J Peto, F Marme, B Burwinkel, P Guénel, T Truong, M Sanchez, C Mulot, SE Bojesen, BG Nordestgaard, H Flyer, H Brenner, AK Dieffenbach, V Arndt, C Stegmaier, A Mannermaa, V Kataja, V-M Kosma, JM Hartikainen, D Lambrechts, BT Yesilyurt, G Floris, K Leunen, J Chang-Claude, A Rudolph, P Seibold, D Flesch-Janys, X Wang, JE Olson, C Vachon, K Purrington, GG Giles, G Severi, L Baglietto, CA Haiman, BE Henderson, F Schumacher, LL Marchand, J Simard, M Dumont, MS Goldberg, F Labréche, R Winqvist, K Pylkäs, A Jukkola-Vuorinen, M Grip, P Devilee, RAEM Tollenaar, C Seynaeve, M García-Closas, SJ Chanock, J Lissowska, JD Figueroa, K Czene, M Eriksson, K Humphreys, H Darabi, MJ Hooning, M Kriege, JM Collée, M Tilanus-Linthorst, J Li, A Jakubowska, J Lubinski, K Jaworska-Bieniek, K Durda, H Nevanlinna, TA Muranen, K Aittomäki, C Blomqvist, N Bogdanova, T Dörk, P Hall, G Chenevix-Trench, DF Easton, PDP Pharroah, JI Arias-Perez, P Zamora, J Benítez, RL Milne
Br J Cancer
BACKGROUND: Breast cancer is one of the most common malignancies in women. Genome-wide association studies have identified FGFR2 as a breast cancer susceptibility gene. Common variation in other fibroblast growth factor (FGF) receptors might also modify risk. We tested this hypothesis by studying genotyped single-nucleotide polymorphisms (SNPs) and imputed SNPs in FGFR1, FGFR3, FGFR4 and FGFRL1 in the Breast Cancer Association Consortium. METHODS: Data were combined from 49 studies, including 53 835 cases and 50 156 controls, of which 89 050 (46 450 cases and 42 600 controls) were of European ancestry, 12 893 (6269 cases and 6624 controls) of Asian and 2048 (1116 cases and 932 controls) of African ancestry. Associations with risk of breast cancer, overall and by disease sub-type, were assessed using unconditional logistic regression. RESULTS: Little evidence of association with breast cancer risk was observed for SNPs in the FGF receptor genes. The strongest evidence in European women was for rs743682 in FGFR3; the estimated per-allele odds ratio was 1.05 (95% confidence interval=1.02-1.09, P=0.0020), which is substantially lower than that observed for SNPs in FGFR2. CONCLUSION: Our results suggest that common variants in the other FGF receptors are not associated with risk of breast cancer to the degree observed for FGFR2.